Duvelisib (under its long chemical name (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one) has been granted orphan drug designation by the EMA for the treatment of chronic lymphocytic leukemia (CLL) and by the FDA for CLL and follicular lymphoma. Duvelisib is in Phase III clinical trial in combination with rituximab or vs. rituximab in patients with previously treated follicular lymphoma (NCT02204982) and Phase II for refractory indolent non-Hodgkin's lymphoma (NCT01882803).

Mechanism Of Action and Pharmacodynamic Effects

Phosphoinositide-3 kinase (PI3K)-δ and PI3K-γ are preferentially expressed in immune cells. Inhibitors targeting these isozymes are hypothesized to modulate both the adaptive and innate immune responses, generating an anti-inflammatory effect .